{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-23-000011","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.270876+00:00","generated_at":"2026-06-08T07:08:50.190617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rallybio reports Q3 2023 net loss of $18.4M ($0.45/share); cash $121.4M, runway into Q1 2025","bullets":["Net loss of $18.4M, or $0.45 per share, unchanged from Q3 2022 net loss of $18.4M ($0.60 per share).","R&D expenses $13.3M (up vs $12.1M in Q3 2022) on advancing RLYB212 and RLYB331; G&A expenses $6.1M (down from $6.8M).","Cash, cash equivalents and marketable securities $121.4M as of Sept 30, 2023; expected to fund operations into Q1 2025.","On track for 4Q 2023 data readouts: RLYB212 Phase 1 multiple dose cohort initial data and RLYB116 Phase 1 MAD data including safety, PK, PD.","RLYB212 Phase 2 dose confirmation study in pregnant women expected to initiate in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-23-000011","json":"https://secwatch.observer/filing/0001739410-23-000011.json","markdown":"https://secwatch.observer/filing/0001739410-23-000011.md","text":"https://secwatch.observer/filing/0001739410-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/0001739410-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/rlyb-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:08:50.190617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e608475ba44083fdc26032db495e5e881c066db","claim":"Rallybio Corp reported the third quarter ended September 30, 2023 results: net income Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45, EPS net loss per common share of $0.45.","evidence_excerpt":"Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/0001739410-23-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45"},{"label":"EPS","value":"net loss per common share of $0.45"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}